Article Text

Download PDFPDF

680 Adaptive design elements in a Ph 1–2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment
  1. Shiraj Sen1,
  2. Andrae L Vandross2,
  3. David Sommerhalder3,
  4. Mohamad A Salkeni4,
  5. Myriam N Bouchlaka5,
  6. Damien Cronier6,
  7. Kamal D Puri5,
  8. Nenad Sarapa7,
  9. Lesley Skingley6,
  10. Mikhail Yefimenko6 and
  11. Alice S Bexon6
  1. 1NEXT Oncology, Dallas, TX, USA
  2. 2NEXT Oncology, Austin, TX, USA
  3. 3NEXT Oncology, San Antonio, TX, USA
  4. 4NEXT Oncology, Fairfax, VA, USA
  5. 5OncoResponse, Inc., Seattle, WA, USA
  6. 6Bexon Clinical Consulting, Montclair, NJ, USA
  7. 7OncoResponse, Inc., Montclair, NJ, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.

Abstract

Background OR502 blocks LILRB2 binding to HLA-class I proteins and prevents LILRB2-mediated immune suppression by myeloid cells. It potentiates Th1-like innate immune responses, rescues T-cells from M2c macrophage-mediated immune suppression and restores T-cell proliferation and effector functions. OR502 reduces and prevents immunosuppressive phenotype of existing and new tumor-associated macrophages (TAMs) and amplifies anti-PD-1 activity in M2c/T-cell coculture. By targeting TAMs, OR502 showed preclinical activity as monotherapy and in combination with cemiplimab.1

FDA’s draft guidance on dose optimization (Project Optimus2) has made the Phase 1–2 development of novel immunotherapies like OR502 more challenging, requiring demonstration of dose-response, and identifying the minimal effective dose prior to later-phase trials.

Methods We designed the OR502-101 study to address standard Phase 1 objectives and the new objectives of Project Optimus (figure 1), including expansion cohorts at different doses (NCT06090266). The monotherapy and combination dose escalations used a modified toxicity probability interval-2 design targeting a dose-limiting toxicity (DLT) rate of 25% with an equivalence interval of 20–30%. The DLT definition included most Grade ≥3 hematological or non-hematological toxicities, with standard exceptions.

As Phase 1 neared completion at the highest dose, we realized we lacked data in the tumor types planned for Part B expansion, but we had observed early signals in other tumor types. It also became clear from further FDA interactions that we should first demonstrate objective efficacy rather than pharmacodynamic signals before exploring dose-response in the indication(s) with demonstrated efficacy. Although we had not anticipated this specific scenario, the protocol’s adaptive elements (table 1) provided flexibility to modify the study design without amendment and with Safety Committee oversight. The adaptive design also allowed expansions at different doses, providing valuable additional pharmacokinetic (PK) data.

Results We immediately transitioned into two mini-expansion cohorts (cutaneous melanoma and non-small cell lung cancer) likely to confirm early efficacy signals prior to further dose-response optimization.

Conclusions Adaptive elements are an important design feature of the modern Phase 1 trial, permitting flexibility (with oversight) to execute efficient Phase 1–2 development in immune oncology (IO) without undue delays. Consequently, development of OR502, a novel IO agent, has been particularly rapid in a changing regulatory environment, accelerating a potentially effective new drug towards approval.

Trial Registration NCT06090266.

References

  1. Bouchlaka M, Zuck M, Dinh N, et al. OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses. J Immunother Cancer 2023;11(Suppl 1):A556.

  2. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases. Draft FDA Guidance for Industry, January 2023.

Abstract 680 Figure 1

Original design and modifications using adaptive elements

Abstract 680 Table 1

Adaptive elements providing flexibility in Phase 1–2 design

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.